Rare diseases
Investigational molecules
Locations
Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa
BelgiumRemibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial
BulgariaA study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis
AustriaStudy comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment
BelgiumEvaluation of remibrutinib (LOU064) effectiveness and safety in adult patients with chronic urticaria: A 12-week placebo-controlled study
FranceEfficacy and safety of remibrutinib (LOU064) in adult patients with papulopustular rosacea: a randomized, double‑blind, placebo‑controlled Phase 2 trial
BulgariaStudy on the Effectiveness and Safety of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa
AustriaPhase 1 study of remibrutinib exposure in cerebrospinal fluid after oral dosing in healthy participants
The NetherlandsStudy on the Effects of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa
BulgariaStudy on the Effects of Remibrutinib for Patients with Generalized Myasthenia Gravis
BelgiumStudy of remibrutinib for long-term treatment of adult patients with chronic spontaneous urticaria who completed previous remibrutinib studies
BulgariaStudy on Remibrutinib for Adults with Chronic Inducible Urticaria Uncontrolled by H1-Antihistamines
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.
